INO - CTI Biopharma Accelerated Review And Other News: The Good Bad And Ugly Of Biopharma
CTI BioPharma Receives Accelerated Review Tag
CTI BioPharma (CTIC) announced that it has received FDA approval for an accelerated review pathway for Pacritinib. The drug candidate is designed for treating myelofibrosis patients suffering from severe thrombocytopenia or low blood platelets. Myelofibrosis is a type of bone marrow cancer and may cause formation of fibrous scar tissue. It can also lead to weakness, severe anemia, enlargement of spleen and liver and fatigue.
Pursuant to this new understanding with the FDA, CTI will amend the PACIFICA pivotal Phase 3 trial protocol. The amendment will let the company